×
About 810 results

ALLMedicine™ Agammaglobulinemia Center

Research & Reviews  269 results

Inhibition of serum and glucocorticoid-regulated protein kinase-1 aggravates imiquimod-...
https://doi.org/10.1016/j.jid.2022.12.013
The Journal of Investigative Dermatology; Meng Q, Bai M et. al.

Jan 10th, 2023 - While the anti-inflammatory effect of serum and glucocorticoid-regulated protein kinase 1 (SGK1) has been established in other diseases, the possible regulatory role of SGK1 in psoriasis and the underlying molecular mechanisms remain largely unkno...

Relapsing Helicobacter cinaedi Cellulitis without Bacteremia in a Patient with X-linked...
https://www.ncbi.nlm.nih.gov/pubmed/36537682
Skinmed Lenskaya V, O'Connor M et. al.

Dec 21st, 2022 - A 23-year-old man with Bruton's X-linked agammaglobulinemia (XLA), who required intravenous immunoglobulin G (IgG) every 3 weeks, presented with an erythematous scaly eruption adjacent to the chest port for antibiotic therapy (Figures 1A,B). His p...

A case of rare splice-site Bruton's tyrosine kinase mutation with atypical X-linked aga...
https://doi.org/10.1016/j.anai.2022.12.004
Annals of Allergy, Asthma & Immunology : Official Publica... Park SE, Neaves BI et. al.

Dec 13th, 2022 - A case of rare splice-site Bruton's tyrosine kinase mutation with atypical X-linked agammaglobulinemia.|2022|Park SE,Neaves BI,Adams K,|

Human adenoviral (HAdV) chronic arthritis expands the infectious spectrum of primary ag...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623974
Virology Journal; de Frémont GM, Salmona M et. al.

Nov 2nd, 2022 - Inborn errors of immunity (IEI) are a heterogeneous entity with an increasing number of late diagnoses. Besides infections, inflammatory manifestations are a growing part of the clinical landscape of IEI. These complications are of unknown causes ...

Immunogenicity and Safety of the Spikevax® (Moderna) mRNA SARS-CoV-2 Vaccine in Patient...
https://doi.org/10.1159/000526375
International Archives of Allergy and Immunology; Kralickova P, Jankovicova K et. al.

Oct 7th, 2022 - Reports on the immunogenicity and efficacy of the Spikevax® vaccine against SARS-CoV-2 in immunodeficient patients are still scarce. We aimed to evaluate the safety and immunogenicity of the vaccine in patients with primary humoral immunodeficienc...

see more →

Drugs  24 results see all →

Clinicaltrials.gov  6 results

COVID-19 Vaccine Responses in PIDD Subjects
https://clinicaltrials.gov/ct2/show/NCT05321407

Apr 11th, 2022 - Individuals with primary and secondary antibody immunodeficiency are at higher risk for severe COVID-19 disease. Humoral immunity is thought to be the predominant protection against COVID-19, however mRNA vaccines have been shown to elicit both an...

Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)
https://clinicaltrials.gov/ct2/show/NCT00161993

Aug 24th, 2021 - The purpose of this study is to determine the pharmacokinetics, efficacy and safety of Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution in subjects with primary immunodeficiency (PID) manifesting as hypo- or agammaglo...

Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia
https://clinicaltrials.gov/ct2/show/NCT01441882

Apr 8th, 2021 - PRIMARY OBJECTIVES: I. To estimate the biologic target activity of dasatinib in CLL patients found to have pre-treatment in vitro dasatinib cytotoxicity (as defined by a >= 50% decrease in absolute lymphocyte count and/or bone marrow CLL count and...

Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency
https://clinicaltrials.gov/ct2/show/NCT02199496

Aug 24th, 2020 - The purpose of this study is to assess the safety/tolerability and efficacy of using ustekinumab in subjects with common variable immunodeficiency CVID or selective IgG subclass deficiency (functional agammaglobulinemia) who have associated sympto...

Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older
https://clinicaltrials.gov/ct2/show/NCT02960399

May 31st, 2018 - Common variable immune deficiency (CVID), specific antibody deficiency (SAD), and X-linked agammaglobulinemia (XLA) are among the most common primary antibody deficiencies in which the mainstay of treatment is gammaglobulin replacement. The use of...

see more →

News  20 results

Tisagenlecleucel Approaches EU Approval for Relapsed/Refractory Follicular Lymphoma
https://www.onclive.com/view/tisagenlecleucel-approaches-eu-approval-for-relapsed-refractory-follicular-lymphoma

Apr 28th, 2022 - The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of tisagenlecleucel (Kymriah) for use in adult patients with relapsed/refractory follicular lymphoma following ...

Byrd Discusses Optimizing Ibrutinib and Idelalisib in CLL
https://www.onclive.com/view/byrd-discusses-optimizing-ibrutinib-and-idelalisib-in-cll

Dec 20th, 2020 - John C. Byrd, MD In a presentation at the inaugural ASH Meeting on Hematologic Malignancies, John C. Byrd, MD, discussed what his clinical experience has revealed about the optimal use of ibrutinib (Imbruvica) and idelalisib (Zydelig) in chronic ...

Ibrutinib Represents "Transformative" Approach in CLL Treatment
https://www.onclive.com/view/ibrutinib-represents-transformative-approach-in-cll-treatment

Dec 5th, 2020 - Jennifer R. Brown, MD, PhD Jennifer R. Brown, MD, PhD, and John Byrd, MD, leading researchers in the emerging field of Bruton tyrosine kinase (BTK) inhibition in chronic lymphocytic leukemia (CLL) and other B-cell malignancies, discussed key ques...

BTK Inhibitor Success Puts Focus on Resistance Mechanisms
https://www.onclive.com/view/btk-inhibitor-success-puts-focus-on-resistance-mechanisms

Dec 5th, 2020 - Krithika Subramanian, PhD Less than 5 years after Bruton tyrosine kinase (BTK) inhibition was introduced in hematologic malignancies, the need for strategies to address primary and secondary mechanisms of resistance has emerged. The robust poten...

The Changing Treatment Landscape in MCL and CLL: A Review of Standards of Care
https://www.onclive.com/view/the-changing-treatment-landscape-in-mcl-and-cll-a-review-of-standards-of-care

Dec 5th, 2020 - Non-Hodgkin Lymphoma (NHL) is 1 of the 10 most common malignancies, accounting for approximately 3% to 4% of cancer cases worldwide.1 Over 30 different subtypes of NHL have been identified.2 Of these, B-cell lymphomas make up the majority of cases...

see more →

Patient Education  5 results see all →